April 28, 2023

CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock

VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of its underwritten confidentially marketed public offering […]
Linea Mercati Interview 4/26/23
This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.
Read more